Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study

奥拉帕尼 支票2 种系突变 医学 肿瘤科 生殖系 癌症 内科学 癌症研究 乳腺癌 突变 BRCA突变 遗传学 生物 基因 聚合酶 聚ADP核糖聚合酶
作者
Sofie Joris,Hannelore Denys,Joëlle Collignon,Marika Rasschaert,Daphné t'Kint de Roodenbeke,François Duhoux,Jean Luc Canon,Sabine Tejpar,Jeroen Mebis,Lore Decoster,Philippe Aftimos,Jacques De Grève
出处
期刊:ESMO open [Elsevier BV]
卷期号:8 (6): 102041-102041
标识
DOI:10.1016/j.esmoop.2023.102041
摘要

•Advanced cancer patients harboring somatic or germline BRCA1/2 mutations respond to treatment with olaparib.•Response to olaparib in the presence of a BRCA1/2 mutation is seen in any cancer type.•Olaparib does not have clinically meaningful activity in cancers with an ATM or CHEK2 mutation. BackgroundThe Belgian Precision initiative aims to maximize the implementation of tumor-agnostic next-generation sequencing in patients with advanced cancer and enhance access to molecularly guided treatment options. Academic tumor-agnostic basket phase II studies are part of this initiative. The current investigator-driven trial aimed to investigate the efficacy of olaparib in advanced cancers with a (likely) pathogenic mutation (germline or somatic) in a gene that plays a role in homologous recombination (HR).Patients and methodsThis open-label, multi-cohort, phase II study examines the efficacy of olaparib in patients with an HR gene mutation in their tumor and disease progression on standard of care. Patients with a somatic or germline mutation in the same gene define a cohort. For each cohort, a Simon minimax two-stage design was used. If a response was observed in the first 13 patients, 14 additional patients were included. Here, we report the results on four completed cohorts: patients with a BRCA1, BRCA2, CHEK2 or ATM mutation.ResultsThe overall objective response rate across different tumor types was 11% in the BRCA1-mutated (n = 27) and 21% in the BRCA2-mutated (n = 27) cohorts. Partial responses were seen in pancreatic cancer, gallbladder cancer, endocrine carcinoma of the pancreas and parathyroid cancer. One patient with a BRCA2 germline-mutated colon cancer has an ongoing complete response with 19+ months on treatment. Median progression-free survival in responding patients was 14+ months (5-34+ months). The clinical benefit rate was 63% in the BRCA1-mutated and 46% in the BRCA2-mutated cohorts. No clinical activity was observed in the ATM (n = 13) and CHEK2 (n = 14) cohorts.ConclusionOlaparib showed efficacy in different cancer types harboring somatic or germline mutations in the BRCA1/2 genes but not in ATM and CHEK2. Patients with any cancer type harboring BRCA1/2 mutations should have access to olaparib. The Belgian Precision initiative aims to maximize the implementation of tumor-agnostic next-generation sequencing in patients with advanced cancer and enhance access to molecularly guided treatment options. Academic tumor-agnostic basket phase II studies are part of this initiative. The current investigator-driven trial aimed to investigate the efficacy of olaparib in advanced cancers with a (likely) pathogenic mutation (germline or somatic) in a gene that plays a role in homologous recombination (HR). This open-label, multi-cohort, phase II study examines the efficacy of olaparib in patients with an HR gene mutation in their tumor and disease progression on standard of care. Patients with a somatic or germline mutation in the same gene define a cohort. For each cohort, a Simon minimax two-stage design was used. If a response was observed in the first 13 patients, 14 additional patients were included. Here, we report the results on four completed cohorts: patients with a BRCA1, BRCA2, CHEK2 or ATM mutation. The overall objective response rate across different tumor types was 11% in the BRCA1-mutated (n = 27) and 21% in the BRCA2-mutated (n = 27) cohorts. Partial responses were seen in pancreatic cancer, gallbladder cancer, endocrine carcinoma of the pancreas and parathyroid cancer. One patient with a BRCA2 germline-mutated colon cancer has an ongoing complete response with 19+ months on treatment. Median progression-free survival in responding patients was 14+ months (5-34+ months). The clinical benefit rate was 63% in the BRCA1-mutated and 46% in the BRCA2-mutated cohorts. No clinical activity was observed in the ATM (n = 13) and CHEK2 (n = 14) cohorts. Olaparib showed efficacy in different cancer types harboring somatic or germline mutations in the BRCA1/2 genes but not in ATM and CHEK2. Patients with any cancer type harboring BRCA1/2 mutations should have access to olaparib.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lx完成签到 ,获得积分10
1秒前
Lucas的应助被曹牛牛采纳,获得10
1秒前
fortuna发布了新的文献求助10
1秒前
二指弹完成签到 ,获得积分10
1秒前
1秒前
2秒前
长阶词完成签到,获得积分10
2秒前
我是老大的应助被duduqiang采纳,获得10
2秒前
李嘉怡完成签到,获得积分20
2秒前
自由逐风的小驴子完成签到,获得积分10
2秒前
2秒前
2秒前
ZHI完成签到,获得积分10
2秒前
bkagyin的应助被zhu采纳,获得10
3秒前
小肖没烦恼完成签到,获得积分10
3秒前
顾矜的应助被刘承昭采纳,获得10
4秒前
英吉利25发布了新的文献求助50
4秒前
4秒前
贺鹏霖完成签到,获得积分10
4秒前
4秒前
quester完成签到,获得积分10
4秒前
5秒前
Ni1101发布了新的文献求助10
5秒前
5秒前
lucy完成签到,获得积分10
6秒前
谦让疾发布了新的文献求助30
6秒前
cc完成签到,获得积分10
7秒前
汉堡包的应助被犹豫的牛排采纳,获得30
8秒前
mw完成签到,获得积分20
8秒前
过时的疾发布了新的文献求助10
9秒前
9秒前
9秒前
852的应助被黑猫黑猫采纳,获得10
9秒前
9秒前
蒸汽秋葵的应助被笑点低愫采纳,获得10
10秒前
英姑的应助被小白狗采纳,获得10
10秒前
tong发布了新的文献求助10
10秒前
玛卡巴卡发布了新的文献求助30
10秒前
10秒前
小猪熊完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160467
求助须知:如何正确求助?哪些是违规求助? 9555463
关于积分的说明 21728123
捐赠科研通 7750270
什么是DOI,文献DOI怎么找? 3427393
关于科研通互助平台的介绍 2552425
邀请新用户注册赠送积分活动 2471741